AR032586A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
AR032586A1
AR032586A1 ARP000102748A ARP000102748A AR032586A1 AR 032586 A1 AR032586 A1 AR 032586A1 AR P000102748 A ARP000102748 A AR P000102748A AR P000102748 A ARP000102748 A AR P000102748A AR 032586 A1 AR032586 A1 AR 032586A1
Authority
AR
Argentina
Prior art keywords
protease inhibitor
hiv protease
pharmaceutical composition
long chain
chain fatty
Prior art date
Application number
ARP000102748A
Other languages
English (en)
Inventor
Soumojeet Ghosh
Laman Al-Razzak Alani
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR032586(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR032586A1 publication Critical patent/AR032586A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica que es una solucion que incluye: (a) un compuesto inhibidor de VIH proteasa o una combinacion de compuestos inhibidores de VIH proteasa, o sales aceptables para uso farmacéuticos de los mismos; (b) un solvente orgánico aceptAble para uso farmacéutico el cual incluye un ácido graso de cadena larga o una mezcla de ácidos grasos de cadena larga y etanol; (c) agua; y (d) opcionalmente un tensioactivo aceptable para uso farmacéutico donde dicho compuesto inhibidor de VIH proteasa posee propiedades de solubilidad mejoradas.
ARP000102748A 1999-06-04 2000-06-02 Composicion farmaceutica AR032586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32582699A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
AR032586A1 true AR032586A1 (es) 2003-11-19

Family

ID=23269615

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000102748A AR032586A1 (es) 1999-06-04 2000-06-02 Composicion farmaceutica
ARP070105573A AR064309A2 (es) 1999-06-04 2007-12-12 Composicion farmaceutica de ritonavir

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070105573A AR064309A2 (es) 1999-06-04 2007-12-12 Composicion farmaceutica de ritonavir

Country Status (33)

Country Link
EP (2) EP1733725B2 (es)
JP (1) JP4753511B2 (es)
KR (1) KR100815412B1 (es)
CN (2) CN100418527C (es)
AR (2) AR032586A1 (es)
AT (2) ATE332132T1 (es)
AU (1) AU778198B2 (es)
BG (1) BG65445B1 (es)
BR (1) BR0007294A (es)
CA (1) CA2371109C (es)
CL (1) CL2008003491A1 (es)
CO (1) CO5160323A1 (es)
CY (2) CY1105237T1 (es)
CZ (1) CZ301308B6 (es)
DE (2) DE60042092D1 (es)
DK (2) DK1733725T4 (es)
ES (2) ES2265946T3 (es)
HK (1) HK1045804A1 (es)
HU (1) HU229501B1 (es)
IL (3) IL146025A0 (es)
MX (1) MXPA01012478A (es)
MY (1) MY127908A (es)
NO (1) NO328968B1 (es)
NZ (1) NZ515016A (es)
PL (1) PL197671B1 (es)
PT (2) PT1183026E (es)
SA (1) SA00210237B1 (es)
SI (2) SI1183026T1 (es)
SK (2) SK286305B6 (es)
TR (1) TR200103488T2 (es)
TW (1) TWI244390B (es)
WO (1) WO2000074677A2 (es)
ZA (1) ZA200108641B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
JP4769400B2 (ja) * 2000-01-19 2011-09-07 アボット・ラボラトリーズ 改良された医薬配合物
JP2005508294A (ja) * 2001-05-25 2005-03-31 アボット・ラボラトリーズ リトナビルおよび／またはロピナビルを含む軟弾性カプセル
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
SG170796A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2015258296B2 (en) * 2006-07-07 2017-08-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2013204805C1 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015234299B2 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2546378T3 (es) * 2006-07-07 2015-09-23 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
NO347119B1 (no) * 2006-07-07 2023-05-15 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
CA2669938C (en) 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
EA019893B1 (ru) * 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
EP2487168A1 (en) 2007-02-23 2012-08-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2013204817B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2438275T3 (es) * 2007-07-06 2014-01-16 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) † 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ES2270426T3 (es) * 1994-03-18 2007-04-01 Supernus Pharmaceuticals, Inc. Sistema de suministros de farmacos emulsionados.
DE4431489A1 (de) * 1994-09-03 1996-03-07 Heidelberger Baustofftech Gmbh Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2000502997A (ja) * 1995-12-13 2000-03-14 アボツト・ラボラトリーズ レトロウイルスプロテアーゼ抑制化合物
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations

Also Published As

Publication number Publication date
PL197671B1 (pl) 2008-04-30
MY127908A (en) 2006-12-29
HK1045804A1 (en) 2002-12-13
KR20020011994A (ko) 2002-02-09
JP4753511B2 (ja) 2011-08-24
TR200103488T2 (tr) 2002-04-22
IL216686A (en) 2014-01-30
SK287185B6 (sk) 2010-02-08
MXPA01012478A (es) 2003-10-14
ES2265946T3 (es) 2007-03-01
BR0007294A (pt) 2002-08-27
CY1105237T1 (el) 2010-03-03
EP1733725A1 (en) 2006-12-20
KR100815412B1 (ko) 2008-03-20
CN101361723B (zh) 2013-11-06
PT1183026E (pt) 2006-11-30
DE60029219D1 (de) 2006-08-17
SI1183026T1 (sl) 2006-10-31
EP1183026B1 (en) 2006-07-05
NO20015670D0 (no) 2001-11-20
WO2000074677A2 (en) 2000-12-14
DE60029219T2 (de) 2007-06-28
ATE332132T1 (de) 2006-07-15
NO328968B1 (no) 2010-06-28
ATE429224T1 (de) 2009-05-15
CZ301308B6 (cs) 2010-01-06
ES2324549T3 (es) 2009-08-10
DK1183026T3 (da) 2006-11-06
NO20015670L (no) 2001-11-20
EP1733725B2 (en) 2012-08-08
SI1733725T2 (sl) 2012-10-30
HUP0201591A3 (en) 2002-10-28
IL146025A (en) 2012-04-30
IL216686A0 (en) 2012-01-31
SI1733725T1 (sl) 2009-08-31
ZA200108641B (en) 2003-01-20
CA2371109A1 (en) 2000-12-14
CO5160323A1 (es) 2002-05-30
CN1353607A (zh) 2002-06-12
CN101361723A (zh) 2009-02-11
DK1733725T4 (da) 2012-09-17
CN100418527C (zh) 2008-09-17
BG106239A (en) 2002-08-30
AU778198B2 (en) 2004-11-25
SA00210237B1 (ar) 2006-11-07
AR064309A2 (es) 2009-03-25
EP1733725B1 (en) 2009-04-22
IL146025A0 (en) 2002-07-25
CY1109135T1 (el) 2014-07-02
HUP0201591A2 (en) 2002-09-28
CZ20014293A3 (cs) 2002-03-13
ES2324549T5 (es) 2012-10-31
TWI244390B (en) 2005-12-01
PL351943A1 (en) 2003-07-14
CA2371109C (en) 2011-04-26
WO2000074677A3 (en) 2001-02-22
EP1183026A2 (en) 2002-03-06
SK286305B6 (en) 2008-07-07
DK1733725T3 (da) 2009-08-03
PT1733725E (pt) 2009-06-30
NZ515016A (en) 2004-02-27
AU5287700A (en) 2000-12-28
CL2008003491A1 (es) 2009-03-06
BG65445B1 (bg) 2008-08-29
HU229501B1 (hu) 2014-01-28
JP2003501386A (ja) 2003-01-14
SK17202001A3 (sk) 2002-03-05
DE60042092D1 (de) 2009-06-04

Similar Documents

Publication Publication Date Title
AR032586A1 (es) Composicion farmaceutica
AR010634A1 (es) Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
PE20030865A1 (es) Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ATE409461T1 (de) Hfc lösungsformulierungen enthaltend ein anticholinergikum
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
CU23873B1 (es) Nuevo procedimiento para la preparación de un intermediario útil en la preparación de imidazotriazinonas sustituidas con sulfonamida
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
CR6106A (es) Desnaturalizantes para sales aminas simpaticomimeticas
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
ES2147837T3 (es) Nuevos compuestos heterociclicos.
AR079399A2 (es) Procedimientos para preparar bifenazato
DK1513526T3 (da) Phenylalkansyre- og phenyloxyalkansyrederivater som hPPAR-aktivatorer
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
CL2008003324A1 (es) Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis.
AR056014A1 (es) Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
SV2002000301A (es) Composicion farmaceutica ref. z-1032
EA200300481A1 (ru) Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов
PA8534001A1 (es) Derivados de piperazina 1,4-disustituida utiles como bloqueadores alfa1,-adrenoceptores uro-selectivos
AR032455A1 (es) Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
ES2060592T3 (es) Un tioester y su uso en la preparacion de composiciones farmaceuticas para el tratamiento de los sindromes de isquemia y reperfusion.
AR023819A1 (es) FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
BG66112B1 (bg) Подобрени фармацевтични състави

Legal Events

Date Code Title Description
FC Refusal